Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Egyptian International Pharmaceutical Investments's EBIT per Share for the
three
months ended in Mar. 2026 was E£4.17.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was E£14.63.
During the past 12 months, the average EBIT per Share Growth Rate of Egyptian International Pharmaceutical Investments was 63.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 18.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
CAI:PHAR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 18.5 Med: 18.5 Max: 18.5
Current: 18.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Egyptian International Pharmaceutical Investments was 18.50% per year. The lowest was 18.50% per year. And the median was 18.50% per year.
CAI:PHAR's 3-Year EBIT Growth Rate is ranked better than 66.75% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.55
vs CAI:PHAR: 18.50
Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Egyptian International Pharmaceutical Investments EBIT per Share Related Terms
Egyptian International Pharmaceutical Investments EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments EBIT per Share Chart
Egyptian International Pharmaceutical Investments Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£14.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a EBIT per Share of E£14.63 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Egyptian International Pharmaceutical Investments and its competitors. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #270 out of 812 companies in the Drug Manufacturers industry, placing it in the top 33.3%.
Is Egyptian International Pharmaceutical Investments' EBIT per Share too high?
Egyptian International Pharmaceutical Investments' current EBIT per Share is E£14.63. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #270 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #270 out of 812 companies for EBIT per Share. This puts Egyptian International Pharmaceutical Investments in the upper half of its industry. The industry median EBIT per Share is 7.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.55, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current EBIT per Share is E£14.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.88, compared to a current price of E£90.70 — trading 51.5% above its estimated fair value. The current EBIT per Share is E£14.63. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current EBIT per Share is E£14.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£90.70 is trading 51.5% above its estimated GF Value™ of E£59.88.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
EBIT per Share: E£14.63
GF Value™: E£59.88 vs. price of E£90.70 (51.5% above fair value)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score
Get the complete analysis for CAI:PHAR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
